AbbVie Stock Dives As Aesthetics Sales Mar Its Third-Quarter Beat And Guidance Boost

AbbVie (ABBV) posted a nearly perfect third-quarter beat Friday, but AbbVie stock skidded on light aesthetics sales and as Humira sales continued to plummet.

During the September quarter, AbbVie earned an adjusted $2.95 per share on $13.93 billion in revenue.